Monday, May 21, 2012

Get the most detailed up-to-date strategies for moving your products into pharmerging markets!

Suzanne Munck, FTC
At past IIR “Generic Drug Summits”, our expert speaking faculty has always provided the most valuable event of the year in terms of sharing crucial and exclusive knowledge about the compliance and commercialization hurdles that you faced on a day-to-day basis. Now more than ever, the insight that we offer in our 13th annual Business of Biosimilars and Generic Drugs conference can help your company stay on top of the latest regulatory developments while capitalizing on new and untapped markets.

Our unequaled speaking faculty this year will provide you with the market-specific case studies and commercialization tactics that you need in order to expand your product portfolio and capitalize on growing global demand! Featured speakers include:

  • - Andrew Shaw, Senior Director, PKDM, Mylan presenting “Establish R&D Methods and Timetables that will Streamline your Expansion into New Markets”
  • - Abdullah Baaj, CEO, Boston Oncology presenting “Getting Global Manufacturing Processes Prepared for Product Rollouts”
  • - Suzanne Munck, Chief Counsel for Intellectual Property, FTC presenting "Turn Antitrust Laws to Your Advantage in the Generics and Biosimilars Marketplace"

For more about these presentations and the rest of the program, download the brochure here.

The 13th Annual Business of Biosimilars and Generic Drugs will take place September 10-12, 2012 in Boston, MA. As a reader of this blog, you receive an exclusive discount of 25% off of the standard price when you register to join us. Simply use priority code XP1786LINK. Have any questions about the event? Feel free to contact Jennifer Pereira.

Share this article with your social network, just click below to share now!

No comments :

Post a Comment